CMND vs. DRRX, LSB, CARA, CTXR, BCAB, NXTC, ENLV, MTEX, INAB, and LSTA
Should you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include DURECT (DRRX), Lakeshore Biopharma (LSB), Cara Therapeutics (CARA), Citius Pharmaceuticals (CTXR), BioAtla (BCAB), NextCure (NXTC), Enlivex Therapeutics (ENLV), Mannatech (MTEX), IN8bio (INAB), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.
Clearmind Medicine vs.
DURECT (NASDAQ:DRRX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
DURECT has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
Clearmind Medicine has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Clearmind Medicine's return on equity of -129.21% beat DURECT's return on equity.
In the previous week, DURECT had 2 more articles in the media than Clearmind Medicine. MarketBeat recorded 2 mentions for DURECT and 0 mentions for Clearmind Medicine. DURECT's average media sentiment score of 0.00 equaled Clearmind Medicine'saverage media sentiment score.
DURECT received 316 more outperform votes than Clearmind Medicine when rated by MarketBeat users.
28.0% of DURECT shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 3.2% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
DURECT currently has a consensus target price of $5.00, suggesting a potential upside of 537.43%. Given DURECT's stronger consensus rating and higher probable upside, analysts plainly believe DURECT is more favorable than Clearmind Medicine.
Clearmind Medicine has lower revenue, but higher earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.
Summary
DURECT beats Clearmind Medicine on 8 of the 15 factors compared between the two stocks.
Get Clearmind Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clearmind Medicine Competitors List
Related Companies and Tools
This page (NASDAQ:CMND) was last updated on 2/22/2025 by MarketBeat.com Staff
